$LUNG
Pulmonx Corp Stock $lung

$lung Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000112753722000037 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$13.50M	$13.95M	$10.79M
YoY Change	1.82%	14.32%	16.67%
Cost Of Revenue	$3.350M	$3.532M	$2.674M
YoY Change	-4.88%	11.28%	1.56%
Gross Profit	$10.15M	$10.42M	$8.111M
YoY Change	4.24%	15.38%	22.69%
Gross Profit Margin	75.19%	74.68%	75.21%
Selling, General & Admin	$19.72M	$21.24M	$20.25M
YoY Change	18.16%	16.64%	25.97%
% of Gross Profit	194.22%	203.83%	249.6%
Research & Development	$4.366M	$3.594M	$3.534M
YoY Change	55.1%	2.51%	16.48%
% of Gross Profit	43.01%	34.5%	43.57%
Depreciation & Amortization	$300.0K	$300.0K	$300.0K
YoY Change	50.0%	200.0%	200.0%
% of Gross Profit	2.96%	2.88%	3.7%
Operating Expenses	$24.08M	$24.83M	$23.78M
YoY Change	23.5%	14.36%	24.46%
Operating Profit	-$13.93M	-$14.41M	-$15.67M
YoY Change	42.71%	13.63%	25.4%
Interest Expense	$286.0K	$223.0K	$198.0K
YoY Change	38.16%	8.25%	-8.76%
% of Operating Profit
Other Income/Expense, Net	-$432.0K	-$165.0K	$0.00
YoY Change	61.8%	71.88%	-100.0%
Pretax Income	-$14.17M	-$14.60M	-$15.76M
YoY Change	39.8%	13.34%	26.65%
Income Tax	$0.00	$40.00K	$100.0K
% Of Pretax Income
Net Earnings	-$14.17M	-$14.64M	-$15.83M
YoY Change	39.2%	12.95%	26.5%
Net Earnings / Revenue	-104.96%	-104.95%	-146.76%
Basic Earnings Per Share	-$0.38	-$0.40	-$0.43
Diluted Earnings Per Share	-$0.38	-$0.40	-$0.43
COMMON SHARES
Basic Shares Outstanding	37.27M shares	37.00M shares	36.81M shares
Diluted Shares Outstanding	37.19M shares	37.00M shares	36.81M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$156.9M	$162.1M	$170.1M
YoY Change	-21.49%	-22.62%	-22.36%
Cash & Equivalents	$112.4M	$121.9M	$129.2M
Short-Term Investments	$44.50M	$40.14M	$40.91M
Other Short-Term Assets	$183.0K	$0.00	$702.0K
YoY Change	-64.74%	-100.0%	28.34%
Inventory	$15.57M	$19.21M	$18.30M
Prepaid Expenses
Receivables	$7.221M	$7.521M	$6.810M
Other Receivables	$398.0K	$25.00K	$277.0K
Total Short-Term Assets	$183.1M	$192.8M	$200.7M
YoY Change	-19.56%	-17.29%	-16.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.922M	$4.932M	$4.918M
YoY Change	4.66%	77.86%	173.37%
Goodwill	$2.300M	$2.300M	$2.300M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$4.684M	$6.379M
YoY Change	-100.0%	131.42%	155.16%
Other Assets	$687.0K	$796.0K	$729.0K
YoY Change	23.12%	42.14%	39.66%
Total Long-Term Assets	$19.09M	$19.95M	$22.12M
YoY Change	-0.43%	25.81%	38.92%
TOTAL ASSETS
Total Short-Term Assets	$183.1M	$192.8M	$200.7M
Total Long-Term Assets	$19.09M	$19.95M	$22.12M
Total Assets	$202.2M	$212.7M	$222.8M
YoY Change	-18.08%	-14.55%	-12.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.648M	$2.599M	$2.803M
YoY Change	-40.28%	20.55%	53.5%
Accrued Expenses	$10.74M	$11.73M	$10.87M
YoY Change	-13.17%	1.58%	6.35%
Deferred Revenue	$106.0K	$131.0K	$132.0K
YoY Change	-32.48%	54.12%	76.0%
Short-Term Debt	$5.043M	$2.921M	$798.0K
YoY Change
Long-Term Debt Due	$5.043M	$2.921M	$798.0K
YoY Change	52.54%	54.63%	69.07%
Total Short-Term Liabilities	$21.69M	$20.45M	$17.72M
YoY Change	-2.39%	17.65%	22.26%
LONG-TERM LIABILITIES
Long-Term Debt	$12.34M	$14.46M	$16.63M
YoY Change	-12.38%	-6.6%	-1.6%
Other Long-Term Liabilities	$0.00	$179.0K	$179.0K
YoY Change	-100.0%	-97.49%	-97.68%
Total Long-Term Liabilities	$12.34M	$14.64M	$16.81M
YoY Change	-43.14%	-35.29%	-31.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.69M	$20.45M	$17.72M
Total Long-Term Liabilities	$12.34M	$14.64M	$16.81M
Total Liabilities	$38.72M	$40.55M	$40.70M
YoY Change	-11.98%	1.19%	4.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$336.0M	-$321.9M	-$307.2M
YoY Change	20.69%	20.02%	20.35%
Common Stock	$498.1M	$492.7M	$487.9M
YoY Change	3.85%	3.59%	3.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$163.5M	$172.2M	$182.1M
YoY Change
Total Liabilities & Shareholders Equity	$202.2M	$212.7M	$222.8M
YoY Change	-18.08%	-14.55%	-12.7%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$14.17M	-$14.64M	-$15.83M
YoY Change	39.2%	12.95%	26.5%
Depreciation, Depletion And Amortization	$300.0K	$300.0K	$300.0K
YoY Change	50.0%	200.0%	200.0%
Cash From Operating Activities	-$10.69M	-$9.564M	-$15.00M
YoY Change	28.53%	-24.65%	54.64%
INVESTING ACTIVITIES
Capital Expenditures	-$279.0K	-$299.0K	$564.0K
YoY Change	-82.78%	-54.9%	133.06%
Acquisitions
YoY Change
Other Investing Activities	$323.0K	$2.379M	-$5.058M
YoY Change	-118.0%	-554.01%	-58.84%
Cash From Investing Activities	$44.00K	$2.080M	-$5.622M
YoY Change	-101.29%	-275.23%	-55.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	906.0K	131.0K	$1.315M
YoY Change	-9.4%	-96.03%	10015.38%
NET CHANGE
Cash From Operating Activities	-10.69M	-9.564M	-$15.00M
Cash From Investing Activities	44.00K	2.080M	-$5.622M
Cash From Financing Activities	906.0K	131.0K	$1.315M
Net Change In Cash	-9.737M	-7.353M	-$19.31M
YoY Change	-9.25%	-30.52%	-13.31%
FREE CASH FLOW
Cash From Operating Activities	-$10.69M	-$9.564M	-$15.00M
Capital Expenditures	-$279.0K	-$299.0K	$564.0K
Free Cash Flow	-$10.41M	-$9.265M	-$15.56M
YoY Change	55.46%	-22.98%	56.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001127537
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39562
	dei	Entity Registrant Name EntityRegistrantName	PULMONX CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0424412
	dei	Entity Address Address Line1 EntityAddressAddressLine1	700 Chesapeake Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	Country Region CountryRegion	1
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	364-0400
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	LUNG
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37268450	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121947000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148480000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	231000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	231000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	40139000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	31561000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7521000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6562000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	19212000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	16285000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3731000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4883000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	192781000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	208002000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4684000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10941000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4814000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	2333000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2333000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	216000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	277000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6987000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8075000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	796000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	731000	usd
CY2022Q2	us-gaap	Assets Assets	212729000	usd
CY2021Q4	us-gaap	Assets Assets	235173000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2599000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1582000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11734000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13366000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	147000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	131000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	163000	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	2921000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	91000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3061000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2201000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20446000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17550000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	47000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	37000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5415000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6844000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14460000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17324000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	40547000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	41934000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37266030	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37266030	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36931762	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36931762	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	37000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	492651000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	482885000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1357000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1712000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321863000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-291395000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	172182000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	193239000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	212729000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235173000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13950000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12203000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24735000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21447000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3532000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3174000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6206000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5807000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	10418000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	9029000	usd
	us-gaap	Gross Profit GrossProfit	18529000	usd
	us-gaap	Gross Profit GrossProfit	15640000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3594000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3506000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7128000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6540000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21235000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18205000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41480000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34276000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	24829000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	21711000	usd
	us-gaap	Operating Expenses OperatingExpenses	48608000	usd
	us-gaap	Operating Expenses OperatingExpenses	40816000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14411000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12682000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30079000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25176000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	199000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	102000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	304000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	207000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	223000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	206000	usd
	us-gaap	Interest Expense InterestExpense	421000	usd
	us-gaap	Interest Expense InterestExpense	423000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-165000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-96000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-165000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14600000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12882000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30361000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25327000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14640000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12962000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30468000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25474000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	66000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-18000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-206000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-92000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	3000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-337000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-86000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	69000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-355000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-206000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14726000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12893000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30823000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25680000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37003443	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37003443	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36042614	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36042614	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36904952	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36904952	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35708548	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35708548	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	193239000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	221000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1108000	usd
CY2022Q1	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	59000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3615000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-24000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-245000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15828000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	182145000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	151000	usd
CY2022Q2	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	58000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4554000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-92000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14640000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	172182000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	226134000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	273000	usd
CY2021Q1	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	66000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2462000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-272000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12512000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	216148000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1133000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1992000	usd
CY2021Q2	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	12000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2476000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	66000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	3000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12962000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	208868000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30468000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25474000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7896000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4580000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	111000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	665000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	744000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	64000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	287000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	32000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-19000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-16000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1226000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1149000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1073000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2732000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3030000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3125000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1065000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-216000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-6000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	29000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1062000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	293000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1296000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2926000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-150000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-87000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-707000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1137000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-11000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-29000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	16000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24590000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22362000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	21959000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	15314000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	19280000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	863000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	903000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3542000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13717000	usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	44000	usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	41000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	382000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1381000	usd
	us-gaap	Proceeds From Repayment Of Loans To Purchase Common Stock ProceedsFromRepaymentOfLoansToPurchaseCommonStock	1108000	usd
	us-gaap	Proceeds From Repayment Of Loans To Purchase Common Stock ProceedsFromRepaymentOfLoansToPurchaseCommonStock	1992000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1446000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3306000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-85000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26533000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32858000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148711000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231792000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122178000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198934000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121947000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198703000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	231000	usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	231000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122178000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198934000	usd
	lung	Increase Lapse In Repurchase Of Common Stock Rights IncreaseLapseInRepurchaseOfCommonStockRights	117000	usd
	lung	Increase Lapse In Repurchase Of Common Stock Rights IncreaseLapseInRepurchaseOfCommonStockRights	78000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	486000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	608000	usd
	lung	Receivable From Exercise Of Common Stock Options ReceivableFromExerciseOfCommonStockOptions	1000	usd
	lung	Receivable From Exercise Of Common Stock Options ReceivableFromExerciseOfCommonStockOptions	25000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	138000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	228000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	226000	usd
	us-gaap	Interest Paid Net InterestPaidNet	375000	usd
	us-gaap	Interest Paid Net InterestPaidNet	360000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Formation and Business of the Company<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the StratX Lung Analysis Platform (“StratX Platform”), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong, and Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $321.9 million as of June 30, 2022. During the six months ended June 30, 2022 and June 30, 2021, the Company used $24.6 million and $22.4 million of cash in its operating activities, respectively. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $166.8 million. Historically, the Company’s activities have been financed through the sale of equity securities, debt financing arrangements and sales of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be widespread significant impact from the COVID-19 pandemic, which has delayed clinical trials and FDA operations and adversely impacted the number of procedures performed using our products. In the markets in which we operate, elective, specialty and other procedures and appointments have been, and continue to be, suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic and the measures taken by many countries in response have materially adversely affected, and could in the future materially adversely affect, our business, financial condition and results of operations, as well as the price of our common stock, from a decrease and delay of procedures involving our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company saw some level of recovery in procedure volumes in our U.S. and larger international markets in the second quarter of 2022, the smaller international markets were hampered by a slower recovery, including continued lockdowns in China. The Company may continue to see regional variations in procedure volumes in the U.S. and international markets from the COVID-19 pandemic and its variants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements reflect judgments and estimates that could change in the future as a result of the COVID-19 pandemic. The COVID-19 pandemic has adversely impacted the Company’s business, financial condition and results of operations by decreasing and delaying procedures performed using its products. While many regions begin to stabilize with improvements in procedure volumes, there continues to be variability and uncertainty as variants of the virus emerge. The Company can make no assurance regarding any future level of demand for the Company’s products, and COVID-19 may adversely impact the results of operations and financial condition.</span></div>
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22400000	usd
CY2022Q2	lung	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	166800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits.
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3500000	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	4600000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-200000	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-200000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-200000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	100000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	45183000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	360000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44823000	usd
CY2021Q4	lung	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	42502000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	40139000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4684000	usd
CY2022Q2	lung	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	44823000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	42526000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	29000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	42502000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	31561000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	10941000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	100000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	100000	usd
CY2022Q2	us-gaap	Cash Cash	117258000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121947000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148480000	usd
CY2021Q4	us-gaap	Cash Cash	141239000	usd
CY2022Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2192000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	831000	usd
CY2022Q2	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	2497000	usd
CY2021Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	2000000	usd
CY2022Q2	lung	Corporate Bonds Debt Securities At Carrying Value CorporateBondsDebtSecuritiesAtCarryingValue	0	usd
CY2021Q4	lung	Corporate Bonds Debt Securities At Carrying Value CorporateBondsDebtSecuritiesAtCarryingValue	4410000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3776000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3738000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	784000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	518000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14652000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12029000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	19212000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	16285000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2886000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1869000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	820000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2305000	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	25000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	362000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	347000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3731000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4883000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7795000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7057000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2863000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2243000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4932000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4814000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	300000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	700000	usd
	us-gaap	Depreciation Depreciation	200000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2300000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	2300000	usd
CY2022Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1849000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1633000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	216000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1849000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1572000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	277000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	62000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	123000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	31000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	216000	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3179000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4741000	usd
CY2022Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2134000	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1850000	usd
CY2022Q2	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	2308000	usd
CY2021Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	2145000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2233000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2420000	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	602000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	730000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11734000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13366000	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	282000	usd
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	399000	usd
CY2022Q2	lung	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	128000	usd
CY2021Q4	lung	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	258000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	868000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	823000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	410000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	7779000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8843000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1510000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	87000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	87000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18716000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	99000	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1236000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	17381000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	100000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	usd
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	usd
CY2020Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q3	lung	Operating Lease Monthly Expense OperatingLeaseMonthlyExpense	100000	usd
CY2020Q3	lung	Operating Lease Expense Annual Increase Rate OperatingLeaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Tenant Improvement Allowance Receivable Upon Lease Renewal TenantImprovementAllowanceReceivableUponLeaseRenewal	200000	usd
CY2013	lung	Lessee Operating Lease Option To Terminate Notice Period LesseeOperatingLeaseOptionToTerminateNoticePeriod	P12M
CY2020Q2	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P3Y
CY2020Q2	lung	Lessee Operating Sublease Option To Terminate Notice Period LesseeOperatingSubleaseOptionToTerminateNoticePeriod	P180D
CY2020Q2	lung	Lessee Operating Sublease Option To Terminate Term LesseeOperatingSubleaseOptionToTerminateTerm	P18M
CY2020Q2	lung	Lessee Operating Sublease Monthly Expense LesseeOperatingSubleaseMonthlyExpense	100000	usd
CY2020Q2	lung	Lessee Operating Sublease Expense Annual Increase Rate LesseeOperatingSubleaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P4Y
CY2020Q3	lung	Lessee Operating Sublease Monthly Expense LesseeOperatingSubleaseMonthlyExpense	100000	usd
CY2020Q3	lung	Lessee Operating Sublease Expense Annual Increase Rate LesseeOperatingSubleaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Lessee Operating Sublease Tenant Improvement Allowance Receivable Upon Lease Renewal LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal	700000	usd
CY2020Q3	lung	Lessee Operating Sublease Renewal Term LesseeOperatingSubleaseRenewalTerm	P12M
CY2020Q3	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P4Y
CY2022Q2	lung	Number Of Vehicle Leases NumberOfVehicleLeases	8	lease
	us-gaap	Operating Lease Cost OperatingLeaseCost	1446000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1452000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	6000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	290000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	293000	usd
	us-gaap	Lease Cost LeaseCost	1752000	usd
	us-gaap	Lease Cost LeaseCost	1751000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1721000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3452000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2919000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1020000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9112000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	636000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	8476000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3061000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5415000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6987000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8075000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M4D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M1D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
	us-gaap	Operating Lease Payments OperatingLeasePayments	966000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1330000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	138000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q2	lung	Number Of Votes For Each Share Of Common Stock Held NumberOfVotesForEachShareOfCommonStockHeld	1	vote
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8786572	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7271132	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2145131	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.44
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	655200	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.56
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172886	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	27208	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.96
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2600237	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.43
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15000000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	904464	shares
CY2022Q2	lung	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	11.56
	lung	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P7Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2600237	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.43
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M3D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7500000	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	12945	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	100000	usd
CY2022Q2	lung	Share Based Payment Arrangement Shares Subject To Repurchase Aggregate Exercise Price ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice	300000	usd
CY2021Q4	lung	Share Based Payment Arrangement Shares Subject To Repurchase Aggregate Exercise Price ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice	400000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4383000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2312000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7896000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4580000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4383000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2312000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7896000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4580000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14640000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14640000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12962000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12962000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30468000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30468000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25474000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25474000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	37171893	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	36324022	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	37090164	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	36021469	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	168450	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	281408	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	185212	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	312921	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37003443	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37003443	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36042614	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36042614	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36904952	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36904952	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35708548	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35708548	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3881205	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3223356	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13950000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12203000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24735000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21447000	usd
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	4932000	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4814000	usd

Files In Submission

Name	View Source	Status
0001127537-22-000037-index-headers.html	Edgar Link	pending
0001127537-22-000037-index.html	Edgar Link	pending
0001127537-22-000037.txt	Edgar Link	pending
0001127537-22-000037-xbrl.zip	Edgar Link	pending
exhibit31_1x080822.htm	Edgar Link	pending
exhibit31_2x080822.htm	Edgar Link	pending
exhibit32_1x080822.htm	Edgar Link	pending
exhibit32_2x080822.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lung-20220630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lung-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
lung-20220630_def.xml	Edgar Link	unprocessable
lung-20220630_pre.xml	Edgar Link	unprocessable
lung-20220630_lab.xml	Edgar Link	unprocessable
lung-20220630_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lung-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUNG
Pulmonx Corp Stock $lung

2022 Q3 Form 10-Q Financial Statement

#000112753722000037 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUNG Pulmonx Corp Stock $lung

2022 Q3 Form 10-Q Financial Statement

#000112753722000037 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUNG
Pulmonx Corp Stock $lung